An Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months.

  • STATUS
    Recruiting
  • days left to enroll
    73
  • participants needed
    3330
  • sponsor
    Sinovac Biotech Co., Ltd
Send
Updated on 22 October 2022
See if I qualify
Accepts healthy volunteers

Summary

The study of quadrivalent influenza vaccine manufactured by Sinovac Biotech Co., Ltd will conduct in two phases,the phaseⅠclinical trial of the study will be open-label design,and the phase III clinical trial of the study will be randomized, double-blind, active controlled design.the purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy subjects aged 6 to 35 months.

Description

This study of quadrivalent influenza vaccine will be open-label design in phase Ⅰ and randomized, double-blind, active controlled design in phase III.The quadrivalent influenza vaccine was manufactured by Sinovac Biotech Co., Ltd.

The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine(0.25ml and 0.5ml) manufactured by Sinovac Biotech Co., Ltd in healthy infants aged from 6 to 35 months. A total of 3330 subjects including 30 subjects in phase Ⅰ and 3300 subjects in phase III will be enrolled. The subjects in phase Ⅰ will receive 2 doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.The subjects in phase III will be randomly assigned to 4 groups in a 2:2:1:1 ratio and subjects will receive two doses of quadrivalent influenza vaccine(0.25ml or 0.5ml) or trivalent influenza vaccine(BV or BY), respectively,on the immunization schedule of day 0,28 in each group.

Details
Condition Seasonal Influenza
Treatment Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV), Trivalent influenza vaccine(BY)
Clinical Study IdentifierNCT05245552
SponsorSinovac Biotech Co., Ltd
Last Modified on22 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Healthy infants aged 6-35 months
Proven vaccination certificate and birth certificate
The subjects' guardians can understand and voluntarily sign the informed consent form

Exclusion Criteria

Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study
Suffering from seasonal influenza in the past 6 moths
Axillary temperature >37.0°C
History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema
Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc
Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders)
Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness
Autoimmune disease or immunodeficiency / immunosuppression
Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition
Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation
Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months
Acute diseases or acute exacerbation of chronic diseases in the past 3 days
Receipt of blood products within in the past 3 months
Receipt of other investigational drugs in the past 30 days
Receipt of attenuated live vaccines in the past 14 days
Receipt of inactivated or subunit vaccines in the past 7 days
Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial
According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Accepts healthy volunteers

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note